Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement .
Outlook Therapeutics to Present at Two Upcoming Investor ConferencesOutlook Therapeutics Reports Topline Results and Positive Proof-of-Concept for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) from NORSE 1Outlook Therapeutics Reports Financial Results for the Third Quarter of Fiscal Year 2020 and Provides Corporate UpdateOutlook Therapeutics Announces Closing of $1.0 Million Private Placement Priced At-The-Market Under Nasdaq RulesOutlook Therapeutics Completes Patient Enrollment for NORSE 2 Study of ONS-5010 / LYTENAVA™ (bevacizumab-vikg)Outlook Therapeutics Announces Closing of $10.2 Million Financing Priced At-The-Market Under Nasdaq RulesOutlook Therapeutics Announces $11.2 Million Financings Priced At-The-Market Under Nasdaq RulesOutlook Therapeutics Provides Clinical Update on ONS-5010 / LYTENAVA™ (bevacizumab-vikg)Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement Outlook Therapeutics to Present at the Virtual Investor Fireside Chat SeriesOutlook Therapeutics Announces Closing of $16.0 Million Private PlacementOutlook Therapeutics Announces $16.0 Million Private Placement to Advance the Development of ONS-5010 / LYTENAVA™ (bevacizumab-vikg)Outlook Therapeutics Reports Financial Results for the Second Quarter of Fiscal Year 2020 and Provides Corporate UpdateOutlook Therapeutics Bolsters Clinical and Commercial Expertise with Two Key Appointments to Board of DirectorsOutlook Therapeutics to Present at the April 2020 Virtual Investor SummitOutlook Therapeutics Provides COVID-19 Impact Update on Ongoing Clinical Trials NORSE 1 and NORSE 2Outlook Therapeutics Announces LYTENAVA™ (bevacizumab-vikg), Anticipated Brand Name for ONS-5010, If ApprovedOutlook Therapeutics Announces Closing of $10.2 Million Financings Priced At-The-MarketOutlook Therapeutics Announces $10.2 Million Financings Priced At-The-MarketOutlook Therapeutics Provides Business Update and Reports Financial Results for the First Quarter of Fiscal Year 2020Outlook Therapeutics to Present at the 2020 BIO CEO & Investor ConferenceOutlook Therapeutics Announces Agreements to Streamline Capital Structure and Regain 100% Ownership of Any Future Net Profits for ONS-5010Outlook Therapeutics Announces Completion of Warrant RestructuringOutlook Therapeutics Announces Warrant Amendment and Restructuring of Senior Secured Notes in Separate TransactionsOutlook Therapeutics Provides Business Update and Reports Financial Results for Fiscal Year 2019Outlook Therapeutics Receives FDA Agreement for Three Special Protocol Assessments for Additional Planned Clinical Trials of ONS-5010Outlook Therapeutics Provides Business Update and Reports Financial Results for Third Quarter of Fiscal 2019Outlook Therapeutics Announces Addition of Jennifer M. Kissner, Ph.D. as Senior Vice President, Clinical DevelopmentOutlook Therapeutics Announces Pricing of Public Offering of Common Stock and WarrantsOutlook Therapeutics Announces FDA Acceptance of IND for ONS-5010Outlook Therapeutics Regains Compliance With All Nasdaq Listing RequirementsOutlook Therapeutics Submits IND Application for ONS-5010 to the FDAOutlook Therapeutics Provides Business Update and Reports First Quarter Financial Results for Fiscal 2019Statement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesInitial Statement of Beneficial Ownership of SecuritiesGeneral Statement of Acquisition of Beneficial OwnershipInitial Statement of Beneficial Ownership of SecuritiesInitial registration statement for securities to be offered to employees pursuant to employee benefit plansStatement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesInitial Statement of Beneficial Ownership of SecuritiesInitial Statement of Beneficial Ownership of SecuritiesGeneral Statement of Acquisition of Beneficial Ownership [Amendment]Statement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesAdditional definitive proxy soliciting materials and rule 14(a)(12) materialStatement of Acquisition of Beneficial Ownership by IndividualsGeneral Statement of Acquisition of Beneficial Ownership [Amendment]Initial Statement of Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesStatement of Acquisition of Beneficial Ownership by IndividualsInitial registration statement for securities to be offered to employees pursuant to employee benefit plansPreliminary Proxy Statement not Related to a Contested Matter or Merger/AcquisitionGeneral Statement of Acquisition of Beneficial Ownership [Amendment]Additional definitive proxy soliciting materials and rule 14(a)(12) materialStatement of Changes in Beneficial Ownership of SecuritiesStatement of Acquisition of Beneficial Ownership by Individuals [Amendment]Statement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesGeneral Statement of Acquisition of Beneficial Ownership [Amendment]Statement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of Securities [Amendment]Statement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesInitial registration statement for securities to be offered to employees pursuant to employee benefit plansStatement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesStatement of Changes in Beneficial Ownership of SecuritiesRegister for free today and gain instant access to over 15,000 stock hubs.
A Deadly Brew, First Grade Math Scope And Sequence, How To Cut Swordfish Steaks, Muggsy Bogues Net Worth, Smooth Jazz Radio Chicago, Muir Beach Picnic, Foreign Nurse In Usa, Laraha Tree, Pozzuoli News, Mylabsplus Login Dccc, Dragon Logo Png, Fallout 4 Silver Shroud Dialogue, Commandos Beyond The Call Of Duty Mission 2, Fedex Tracking Not Updating 2020, Homework Solutions Websites, Banjo Tooie Rom Fix, Biostatistics Cheat Sheet, Homes For Sale Joshua, Tx, Jailbird Paper, Aqui Llegó Tu Tiburón In English, Horrible Films, Relationship Advice Column, Tillamook County Permit Lookup, Bigger Leaner Stronger Equipment Needed, Booking Photos Pinellas County, Florida, Smith's Weekly Ad, Sausalito Sports Bar, College Algebra 2 Problems, 2017 And 2018 Bollywood Movies List, Carry Out Synonym, Scott Foresman Social Studies Grade 3 Pdf, Portland Urban Sprawl, Mawaali Cast, Savoury Crepe Fillings Vegetarian, Obesity In America Articles, Catholic Mass For Beginners, The Incredible Shrinking Man Full Movie Youtube, Round Concrete Fire Pit Diy, Arguing About War,